Literature DB >> 22531331

Adora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury.

Michael Koeppen1, Patrick N Harter, Stephanie Bonney, Megan Bonney, Susan Reithel, Cornelia Zachskorn, Michel Mittelbronn, Tobias Eckle.   

Abstract

BACKGROUND: Cardiac ischemia-reperfusion (I-R) injury represents a major cause of cardiac tissue injury. Adenosine signaling dampens inflammation during cardiac I-R. The authors investigated the role of the adenosine A2b-receptor (Adora2b) on inflammatory cells during cardiac I-R.
METHODS: To study Adora2b signaling on inflammatory cells, the authors transplanted wild-type (WT) bone marrow (BM) into Adora2b(-/-) mice or Adora2b(-/-) BM into WT mice. To study the role of polymorphonuclear leukocytes (PMNs), neutrophil-depleted WT mice were treated with an Adora2b agonist. After treatments, mice were exposed to 60 min of myocardial ischemia and 120 min of reperfusion. Infarct sizes and troponin I concentrations were determined by triphenyltetrazolium chloride staining and enzyme-linked immunosorbent assay, respectively.
RESULTS: Transplantation of WT BM into Adora2b(-/-) mice decreased infarct sizes by 19 ± 4% and troponin I by 87.5 ± 25.3 ng/ml (mean ± SD, n = 6). Transplantation of Adora2b(-/-) BM into WT mice increased infarct sizes by 20 ± 3% and troponin I concentrations by 69.7 ± 17.9 ng/ml (mean ± SD, n = 6). Studies on the reperfused myocardium revealed PMNs as the dominant cell type. PMN depletion or Adora2b agonist treatment reduced infarct sizes by 30 ± 11% or 26 ± 13% (mean ± SD, n = 4); however, the combination of both did not produce additional cardioprotection. Cytokine profiling showed significantly higher cardiac tumor necrosis factor α concentrations in Adora2b(-/-) compared with WT mice (39.3 ± 5.3 vs. 7.5 ± 1.0 pg/mg protein, mean ± SD, n = 4). Pharmacologic studies on human-activated PMNs revealed an Adora2b-dependent tumor necrosis factor α release.
CONCLUSION: Adora2b signaling on BM-derived cells such as PMNs represents an endogenous cardioprotective mechanism during cardiac I-R. The authors' findings suggest that Adora2b agonist treatment during cardiac I-R reduces tumor necrosis factor α release of PMNs, thereby dampening tissue injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531331      PMCID: PMC3360806          DOI: 10.1097/ALN.0b013e318255793c

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  41 in total

1.  A novel adenosine analog, AMP579, inhibits neutrophil activation, adherence and neutrophil-mediated injury to coronary vascular endothelium.

Authors:  M Nakamura; Z Q Zhao; K L Clark; D V Velez; R A Guyton; J Vinten-Johansen
Journal:  Eur J Pharmacol       Date:  2000-05-26       Impact factor: 4.432

2.  Initial sequencing and comparative analysis of the mouse genome.

Authors:  Robert H Waterston; Kerstin Lindblad-Toh; Ewan Birney; Jane Rogers; Josep F Abril; Pankaj Agarwal; Richa Agarwala; Rachel Ainscough; Marina Alexandersson; Peter An; Stylianos E Antonarakis; John Attwood; Robert Baertsch; Jonathon Bailey; Karen Barlow; Stephan Beck; Eric Berry; Bruce Birren; Toby Bloom; Peer Bork; Marc Botcherby; Nicolas Bray; Michael R Brent; Daniel G Brown; Stephen D Brown; Carol Bult; John Burton; Jonathan Butler; Robert D Campbell; Piero Carninci; Simon Cawley; Francesca Chiaromonte; Asif T Chinwalla; Deanna M Church; Michele Clamp; Christopher Clee; Francis S Collins; Lisa L Cook; Richard R Copley; Alan Coulson; Olivier Couronne; James Cuff; Val Curwen; Tim Cutts; Mark Daly; Robert David; Joy Davies; Kimberly D Delehaunty; Justin Deri; Emmanouil T Dermitzakis; Colin Dewey; Nicholas J Dickens; Mark Diekhans; Sheila Dodge; Inna Dubchak; Diane M Dunn; Sean R Eddy; Laura Elnitski; Richard D Emes; Pallavi Eswara; Eduardo Eyras; Adam Felsenfeld; Ginger A Fewell; Paul Flicek; Karen Foley; Wayne N Frankel; Lucinda A Fulton; Robert S Fulton; Terrence S Furey; Diane Gage; Richard A Gibbs; Gustavo Glusman; Sante Gnerre; Nick Goldman; Leo Goodstadt; Darren Grafham; Tina A Graves; Eric D Green; Simon Gregory; Roderic Guigó; Mark Guyer; Ross C Hardison; David Haussler; Yoshihide Hayashizaki; LaDeana W Hillier; Angela Hinrichs; Wratko Hlavina; Timothy Holzer; Fan Hsu; Axin Hua; Tim Hubbard; Adrienne Hunt; Ian Jackson; David B Jaffe; L Steven Johnson; Matthew Jones; Thomas A Jones; Ann Joy; Michael Kamal; Elinor K Karlsson; Donna Karolchik; Arkadiusz Kasprzyk; Jun Kawai; Evan Keibler; Cristyn Kells; W James Kent; Andrew Kirby; Diana L Kolbe; Ian Korf; Raju S Kucherlapati; Edward J Kulbokas; David Kulp; Tom Landers; J P Leger; Steven Leonard; Ivica Letunic; Rosie Levine; Jia Li; Ming Li; Christine Lloyd; Susan Lucas; Bin Ma; Donna R Maglott; Elaine R Mardis; Lucy Matthews; Evan Mauceli; John H Mayer; Megan McCarthy; W Richard McCombie; Stuart McLaren; Kirsten McLay; John D McPherson; Jim Meldrim; Beverley Meredith; Jill P Mesirov; Webb Miller; Tracie L Miner; Emmanuel Mongin; Kate T Montgomery; Michael Morgan; Richard Mott; James C Mullikin; Donna M Muzny; William E Nash; Joanne O Nelson; Michael N Nhan; Robert Nicol; Zemin Ning; Chad Nusbaum; Michael J O'Connor; Yasushi Okazaki; Karen Oliver; Emma Overton-Larty; Lior Pachter; Genís Parra; Kymberlie H Pepin; Jane Peterson; Pavel Pevzner; Robert Plumb; Craig S Pohl; Alex Poliakov; Tracy C Ponce; Chris P Ponting; Simon Potter; Michael Quail; Alexandre Reymond; Bruce A Roe; Krishna M Roskin; Edward M Rubin; Alistair G Rust; Ralph Santos; Victor Sapojnikov; Brian Schultz; Jörg Schultz; Matthias S Schwartz; Scott Schwartz; Carol Scott; Steven Seaman; Steve Searle; Ted Sharpe; Andrew Sheridan; Ratna Shownkeen; Sarah Sims; Jonathan B Singer; Guy Slater; Arian Smit; Douglas R Smith; Brian Spencer; Arne Stabenau; Nicole Stange-Thomann; Charles Sugnet; Mikita Suyama; Glenn Tesler; Johanna Thompson; David Torrents; Evanne Trevaskis; John Tromp; Catherine Ucla; Abel Ureta-Vidal; Jade P Vinson; Andrew C Von Niederhausern; Claire M Wade; Melanie Wall; Ryan J Weber; Robert B Weiss; Michael C Wendl; Anthony P West; Kris Wetterstrand; Raymond Wheeler; Simon Whelan; Jamey Wierzbowski; David Willey; Sophie Williams; Richard K Wilson; Eitan Winter; Kim C Worley; Dudley Wyman; Shan Yang; Shiaw-Pyng Yang; Evgeny M Zdobnov; Michael C Zody; Eric S Lander
Journal:  Nature       Date:  2002-12-05       Impact factor: 49.962

Review 3.  Vascular ischaemia and reperfusion injury.

Authors:  Holger K Eltzschig; Charles D Collard
Journal:  Br Med Bull       Date:  2004-10-19       Impact factor: 4.291

4.  Targeted deletion of A(3) adenosine receptors improves tolerance to ischemia-reperfusion injury in mouse myocardium.

Authors:  R J Cerniway; Z Yang; M A Jacobson; J Linden; G P Matherne
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-10       Impact factor: 4.733

Review 5.  Linking inflammation and coagulation: novel drug targets to treat organ ischemia.

Authors:  Carla Jennewein; Patrick Paulus; Kai Zacharowski
Journal:  Curr Opin Anaesthesiol       Date:  2011-08       Impact factor: 2.706

6.  Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices.

Authors:  E J Birks; N Latif; V Owen; C Bowles; L E Felkin; A J Mullen; A Khaghani; P J Barton; J M Polak; J R Pepper; N R Banner; M H Yacoub
Journal:  Circulation       Date:  2001-09-18       Impact factor: 29.690

7.  Neutrophil function in ischemic heart disease.

Authors:  J Mehta; J Dinerman; P Mehta; T G Saldeen; D Lawson; W H Donnelly; R Wallin
Journal:  Circulation       Date:  1989-03       Impact factor: 29.690

Review 8.  TNFalpha in ischemia/reperfusion injury and heart failure.

Authors:  Rainer Schulz; Stephanie Aker; Sergej Belosjorow; Gerd Heusch
Journal:  Basic Res Cardiol       Date:  2003-08-05       Impact factor: 17.165

9.  Species variation in the coronary collateral circulation during regional myocardial ischaemia: a critical determinant of the rate of evolution and extent of myocardial infarction.

Authors:  M P Maxwell; D J Hearse; D M Yellon
Journal:  Cardiovasc Res       Date:  1987-10       Impact factor: 10.787

10.  Coordinated adenine nucleotide phosphohydrolysis and nucleoside signaling in posthypoxic endothelium: role of ectonucleotidases and adenosine A2B receptors.

Authors:  Holger K Eltzschig; Juan C Ibla; Glenn T Furuta; Martin O Leonard; Kenneth A Jacobson; Keiichi Enjyoji; Simon C Robson; Sean P Colgan
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

View more
  29 in total

1.  Over-expression of JAZF1 promotes cardiac microvascular endothelial cell proliferation and angiogenesis via activation of the Akt signaling pathway in rats with myocardial ischemia-reperfusion.

Authors:  Jie Shang; Zhi-Yong Gao; Li-Yan Zhang; Chun-Yu Wang
Journal:  Cell Cycle       Date:  2019-06-18       Impact factor: 4.534

Review 2.  The Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic Diseases.

Authors:  Anna Eisenstein; Shenia Patterson; Katya Ravid
Journal:  J Cell Physiol       Date:  2015-12       Impact factor: 6.384

Review 3.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

Review 4.  Attenuating myocardial ischemia by targeting A2B adenosine receptors.

Authors:  Holger K Eltzschig; Stephanie K Bonney; Tobias Eckle
Journal:  Trends Mol Med       Date:  2013-03-26       Impact factor: 11.951

5.  ADORA2b Signaling in Cardioprotection.

Authors:  Jennifer Gile; Tobias Eckle
Journal:  J Nat Sci       Date:  2016

6.  Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis.

Authors:  C M Aherne; B Saeedi; C B Collins; J C Masterson; E N McNamee; L Perrenoud; C R Rapp; V F Curtis; A Bayless; A Fletcher; L E Glover; C M Evans; P Jedlicka; G T Furuta; E F de Zoeten; S P Colgan; H K Eltzschig
Journal:  Mucosal Immunol       Date:  2015-04-08       Impact factor: 7.313

7.  Adora2b adenosine receptor signaling protects during acute kidney injury via inhibition of neutrophil-dependent TNF-α release.

Authors:  Almut Grenz; Jae-Hwan Kim; Jessica D Bauerle; Eunyoung Tak; Holger K Eltzschig; Eric T Clambey
Journal:  J Immunol       Date:  2012-10-01       Impact factor: 5.422

8.  Decreased expression of adenosine receptor 2B confers cardiac protection against ischemia via restoring autophagic flux.

Authors:  Enbo Zhan; Wei Cao; Xiaoying Fan; Ruoxi Zhang; Hongwei Du; Yousheng Xu; Lili Li; Nana Dong; Shaojun Li
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

9.  A Role for the Adenosine ADORA2B Receptor in Midazolam Induced Cognitive Dysfunction.

Authors:  Jennifer Gile; Yoshimasa Oyama; Sydney Shuff; Tobias Eckle
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

10.  Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury.

Authors:  Tobias Eckle; Kelly Hughes; Heidi Ehrentraut; Kelley S Brodsky; Peter Rosenberger; Doo-Sup Choi; Katya Ravid; Tingting Weng; Yang Xia; Michael R Blackburn; Holger K Eltzschig
Journal:  FASEB J       Date:  2013-04-19       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.